Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics PathoKey MP UTI ID and AMR PCR Test

Vela Diagnostics has launched the PathoKey MP UTI ID and AMR PCR test for research use only. This multiplex PCR-based test enables the simultaneous in vitro detection and differentiation of 14 pathogens that cause urinary tract infections, as well as 14 antimicrobial resistance genes encoding resistance to five antibiotics. The test is compatible with common real-time PCR platforms such as the Qiagen Rotor-Gene Q 5/6 plex platforms and Thermo Fisher Scientific QuantStudio 5 real-time PCR system. Vela said that its proprietary Sentosa SA201 Reporter can generate a report that consolidates pathogen and AMR results for each sample when used with the Sentosa SA201 or Applied Biosystems 7500 Fast Dx platform.

The test can be implemented in an automated or manual workflow, Vela noted. Higher-throughput laboratories can choose from two of Vela's automated solutions, which incorporate the Sentosa SX101 instrument for extraction and PCR setup, generating a report within four hours with as little as 30 minutes of hands-on time. The second automated workflow includes the Thermo Fisher KingFisher Flex instrument for even higher throughput, Vela said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.